Luminous Mind, Inc.

Boston – October 06, 2026 -- Luminous Mind, Inc. (LMI) has secured U.S. Patent No. 12,697,362, covering technology that produces non-hallucinogenic psychedelic fungi, targeting a functional mushroom market Grand View Research values at $38.2 billion for 2025.

Patent strips psilocybin while preserving secondary metabolites

The patent isolates beneficial compounds found in psilocybin-containing mushrooms -- secondary metabolites and active fungal molecules typically overshadowed by the hallucinogen. By removing psilocybin, LMI says the resulting products retain potential nutraceutical benefits without triggering hallucinations, opening a path to mass-market commercialization that psychedelic-based products cannot access under current regulatory frameworks.